Endothelial function: From vascular biology to clinical applications

American Journal of Cardiology

Volumn 90, Issue 10 SUPPL. 3, 2002, Pages L40-L48

  Behrendt, Dominik ^a,b   Ganz, Peter ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; STATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOOTH MUSCLE FIBER; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION; VASOMOTOR DISORDER;

EID: 0037153047     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(02)02963-6     Document Type: Conference Paper

References (111)

1. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
2. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 84:1987;9265-9269.
3. Furchgott R.F. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA. 276:1996;1186-1188.
4. Palmer R.M., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 333:1988;664-666.
5. Gauthier T.W., Scalia R., Murohara T., Guo J.P., Lefer A.M. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;1652-1659.
6. Kubes P., Suzuki M., Granger D.N. Nitric oxide an endogenous modulator of leukocyte adhesion . Proc Natl Acad Sci U S A. 88:1991;4651-4655.
7. Cornwell T.L., Arnold E., Boerth N.J., Lincoln T.M. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 267:1994;C1405-C1413.
8. de Graaf J.C., Banga J.D., Moncada S., Palmer R.M., de Groot P.G., Sixma J.J. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 85:1992;2284-2290.
9. Luscinskas F.W., Kansas G.S., Ding H., Pizcueta P., Schleiffenbaum B.E., Tedder T.F., Gimbrone M.A. Jr. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta 1-integrins, and beta 2-integrins. J Cell Biol. 125:1994;1417-1427.
10. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration the multistep paradigm . Cell. 76:1994;301-314.
11. Ley K., Tedder T.F. Leukocyte interactions with vascular endothelium. New insights into selectin-mediated attachment and rolling. J Immunol. 155:1995;525-528.
12. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
13. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:2001;365-372.
14. Richardson P.D., Davies M.J., Born G.V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 2:1989;941-944.
15. Lendon C.L., Davies M.J., Born G.V., Richardson P.D. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 87:1991;87-90.
16. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
17. Poston R.N., Haskard D.O., Coucher J.R., Gall N.P., Johnson-Tidey R.R. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 140:1992;665-673.
18. Johnson-Tidey R.R., McGregor J.L., Taylor P.R., Poston R.N. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol. 144:1994;952-961.
19. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 315:1986;1046-1051.
20. Vita J.A., Treasure C.B., Nabel E.G., McLenachan J.M., Fish R.D., Yeung A.C., Vekshtein V.I., Selwyn A.P., Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
21. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
22. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange D., Lieberman E.H., Ganz P., Creager M.A., Yeung A.C., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 26:1995;1235-1241.
23. Anderson T.J., Meredith I.T., Charbonneau F., Yeung A.C., Frei B., Selwyn A.P., Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
24. Yeung A.C., Vekshtein V.I., Krantz D.S., Vita J.A., Ryan T.J. Jr, Ganz P., Selwyn A.P. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 325:1991;1551-1556.
25. Egashira K., Hirooka Y., Kai H., Sugimachi M., Suzuki S., Inou T., Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
26. Zeiher A.M., Krause T., Schachinger V., Minners J., Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 91:1995;2345-2352.
27. Heras M., Sanz G., Roig E., Perez-Villa F., Recasens L., Serra A., Betriu A. Endothelial dysfunction of the non-infarct related, angiographically normal, coronary artery in patients with an acute myocardial infarction. Eur Heart J. 17:1996;715-720.
28. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
29. Uehata A., Lieberman E.H., Gerhard M.D., Anderson T.J., Ganz P., Polak J.F., Creager M.A., Yeung A.C. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med. 2:1997;87-92.
30. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 99:1999;3227-3233.
31. Anderson T.J., Elstein E., Haber H., Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 35:2000;60-66.
32. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery a report of the International Brachial Artery Reactivity Task Force . J Am Coll Cardiol. 39:2002;257-265.
33. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516.
34. Creager M.A., Roddy M.A. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 24:1994;499-505.
35. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 27:1996;567-574.
36. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
37. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 104:2001;2673-2678.
38. Li J., Zhao S.P., Li X.P., Zhuo Q.C., Gao M., Lu S.K. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. Int J Cardiol. 61:1997;165-169.
39. Panza J.A., Quyyumi A.A., Callahan T.S., Epstein S.E. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 21:1993;1145-1151.
40. Creager M.A., Gallagher S.J., Girerd X.J., Coleman S.M., Dzau V.J., Cooke J.P. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 90:1992;1248-1253.
41. Taddei S., Virdis A., Mattei P., Ghiadoni L., Gennari A., Fasolo C.B., Sudano I., Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 91:1995;1981-1987.
42. Celermajer D.S., Sorensen K.E., Georgakopoulos D., Bull C., Thomas O., Robinson J., Deanfield J.E. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 88:1993;2149-2155.
43. Heitzer T., Just H., Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 94:1996;6-9.
44. Heitzer T., Brockhoff C., Mayer B., Warnholtz A., Mollnau H., Henne S., Meinertz T., Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers evidence for a dysfunctional nitric oxide synthase . Circ Res. 86:2000;E36-E41.
45. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:2000;1899-1906.
46. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes D.R. Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:2000;948-954.
47. Neunteufl T., Heher S., Katzenschlager R., Wolfl G., Kostner K., Maurer G., Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol. 86:2000;207-210.
48. Perticone F., Ceravolo R., Pujia A., Ventura G., Iacopino S., Scozzafava A., Ferraro A., Chello M., Mastroroberto P., Verdecchia P., Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 104:2001;191-196.
49. Kojda G., Harrison D. Interactions between NO and reactive oxygen species pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure . Cardiovasc Res. 43:1999;562-571.
50. Gryglewski R.J., Palmer R.M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 320:1986;454-456.
51. Rubanyi G.M., Vanhoutte P.M. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 250:1986;H822-H827.
52. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
53. Guzik T.J., West N.E., Black E., McDonald D., Ratnatunga C., Pillai R., Channon K.M. Vascular superoxide production by NAD(P)H oxidase association with endothelial dysfunction and clinical risk factors . Circ Res. 86:2000;E85-E90.
54. Mugge A., Elwell J.H., Peterson T.E., Hofmeyer T.G., Heistad D.D., Harrison D.G. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res. 69:1991;1293-1300.
55. Landmesser U., Merten R., Spiekermann S., Buttner K., Drexler H., Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease relation to endothelium-dependent vasodilation . Circulation. 101:2000;2264-2270.
56. Ohgushi M., Kugiyama K., Fukunaga K., Murohara T., Sugiyama S., Miyamoto E., Yasue H. Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler Thromb. 13:1993;1525-1532.
57. Liao J.K., Clark S.L. Regulation of G-protein alpha i2 subunit expression by oxidized low-density lipoprotein. J Clin Invest. 95:1995;1457-1463.
58. Kugiyama K., Ohgushi M., Sugiyama S., Murohara T., Fukunaga K., Miyamoto E., Yasue H. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res. 71:1992;1422-1428.
59. Mangin E.L. Jr, Kugiyama K., Nguy J.H., Kerns S.A., Henry P.D. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res. 72:1993;161-166.
60. Murohara T., Kugiyama K., Ohgushi M., Sugiyama S., Ohta Y., Yasue H. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am J Physiol. 267:1994;H2441-H2449.
61. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases the role of oxidant stress . Circ Res. 87:2000;840-844.
62. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., Skatchkov M., Heitzer T., Stasch J.P., Griendling K.K., Harrison D.G., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis evidence for involvement of the renin-angiotensin system . Circulation. 99:1999;2027-2033.
63. Cardillo C., Kilcoyne C.M., Cannon R.O. 3rd, Quyyumi A.A., Panza J.A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 30:1997;57-63.
64. Woodman C.R., Muller J.M., Rush J.W., Laughlin M.H., Price E.M. Flow regulation of ecNOS and Cu/Zn SOD mRNA expression in porcine coronary arterioles. Am J Physiol. 276:1999;H1058-H1063.
65. Uematsu M., Ohara Y., Navas J.P., Nishida K., Murphy T.J., Alexander R.W., Nerem R.M., Harrison D.G. Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. Am J Physiol. 269:1995;C1371-C1378.
66. Hirata K., Miki N., Kuroda Y., Sakoda T., Kawashima S., Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res. 76:1995;958-962.
67. Zembowicz A., Tang J.L., Wu K.K. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem. 270:1995;17006-17010.
68. Inoue N., Venema R.C., Sayegh H.S., Ohara Y., Murphy T.J., Harrison D.G. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol. 15:1995;1255-1261.
69. Yoshizumi M., Perrella M.A., Burnett J.C. Jr, Lee M.E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 73:1993;205-209.
70. Garcia-Cardena G., Martasek P., Masters B.S., Skidd P.M., Couet J., Li S., Lisanti M.P., Sessa W.C. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem. 272:1997;25437-25440.
71. Ju H., Zou R., Venema V.J., Venema R.C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem. 272:1997;18522-19525.
72. 2+-calmodulin and caveolin. J Biol Chem. 272:1997;15583-15586.
73. Feron O., Belhassen L., Kobzik L., Smith T.W., Kelly R.A., Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem. 271:1996;22810-22814.
74. Feron O., Dessy C., Moniotte S., Desager J.P., Balligand J.L. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest. 103:1999;897-905.
75. Scotland R.S., Morales-Ruiz M., Chen Y., Yu J., Rudic R.D., Fulton D., Gratton J.P., Sessa W.C. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res. 90:2002;904-910.
76. Fontana J., Fulton D., Chen Y., Fairchild T.A., McCabe T.J., Fujita N., Tsuruo T., Sessa W.C. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res. 90:2002;866-873.
77. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem. 276:2001;32663-32669.
78. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605.
79. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 399:1999;597-601.
80. Garcia-Cardena G., Fan R., Shah V., Sorrentino R., Cirino G., Papapetropoulos A., Sessa W.C. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 392:1998;821-824.
81. Fleming I., Fisslthaler B., Dimmeler S., Kemp B.E., Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 88:2001;E68-E75.
82. Cooke J.P. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 20:2000;2032-2037.
83. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction dysregulation of dimethylarginine dimethylaminohydrolase . Circulation. 99:1999;3092-3095.
84. Tsao P.S., Cooke J.P. Endothelial alterations in hypercholesterolemia more than simply vasodilator dysfunction . J Cardiovasc Pharmacol. 32:1998;S48-S53.
85. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., Blaschke T.F., Cooke J.P. Asymmetric dimethylarginine (ADMA) a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia . Circulation. 98:1998;1842-1847.
86. Pou S., Pou W.S., Bredt D.S., Snyder S.H., Rosen G.M. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem. 267:1992;24173-24176.
87. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., Pritchard K.A. Jr. Superoxide generation by endothelial nitric oxide synthase the influence of cofactors . Proc Natl Acad Sci U S A. 95:1998;9220-9225.
88. 2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 281:1992;627-630.
89. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., Tarpey M., Fukai T., Harrison D.G. Endothelial regulation of vasomotion in apoE-deficient mice implications for interactions between peroxynitrite and tetrahydrobiopterin . Circulation. 103:2001;1282-1288.
90. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
91. Vogel R.A., Corretti M.C., Plotnick G.D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol. 77:1996;37-40.
92. Stroes E.S., Koomans H.A., de Bruin T.W., Rabelink T.J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 346:1995;467-471.
93. John S., Schlaich M., Langenfeld M., Weihprecht H., Schmitz G., Weidinger G., Schmieder R.E. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients a randomized, placebo-controlled, double-blind study . Circulation. 98:1998;211-216.
94. John S., Delles C., Jacobi J., Schlaich M.P., Schneider M., Schmitz G., Schmieder R.E. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol. 37:2001;1351-1358.
95. Cohen J.D., Drury J.H., Ostdiek J., Finn J., Babu B.R., Flaker G., Belew K., Donohue T., Labovitz A. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels a mechanism for reducing clinical events? Am Heart J. 139:2000;734-738.
96. Harrison D.G., Armstrong M.L., Freiman P.C., Heistad D.D. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 80:1987;1808-1811.
97. Leung W.H., Lau C.P., Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500.
98. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
99. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 31:1998;684-691.
100. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
101. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 95:1998;8880-8885.
102. Kano H., Hayashi T., Sumi D., Esaki T., Asai Y., Thakur N.K., Jayachandran M., Iguchi A. A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels possible relevance of up-regulation of endothelial NO synthase mRNA . Biochem Biophys Res Commun. 259:1999;414-419.
103. Wilson S.H., Simari R.D., Best P.J., Peterson T.E., Lerman L.O., Aviram M., Nath K.A., Holmes D.R. Jr, Lerman A. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 21:2001;122-128.
104. Feron O., Dessy C., Desager J.P., Balligand J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 103:2001;113-118.
105. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010.
106. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 74:1994;1141-1148.
107. Mancini G.B., Henry G.C., Macaya C., O'Neill B.J., Pucillo A.L., Carere R.G., Wargovich T.J., Mudra H., Luscher T.F., Klibaner M.I., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 94:1996;258-265.
108. Antony I., Lerebours G., Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation. 94:1996;3115-3122.
109. Nickenig G., Stablein A., Wassmann S., Wyen C., Muller C., Bohm M. Acute effects of ACE inhibition on coronary endothelial dysfunction. J Renin Angiotensin Aldosterone Syst. 1:2000;361-364.
110. Hornig B., Landmesser U., Kohler C., Ahlersmann D., Spiekermann S., Christoph A., Tatge H., Drexler H. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease role of superoxide dismutase . Circulation. 103:2001;799-805.
111. Kiowski W., Linder L., Nuesch R., Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension. 27:1996;371-376.